Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Filings indexed 1,392 across all filing types
Latest filing 2016-09-09 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2016-09-09 English
PRIMARY DOCUMENT
Director's Dealing
2016-09-07 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 22, 2016, reporting a change in the company's independent registered public accounting firm from Grant Thornton LLP to Ernst & Young LLP. It includes details about the dismissal and engagement of auditors, references to audit reports, and a letter from the former auditor. The content focuses on auditor change notification rather than the audit report itself or full financial statements. The document length is 4681 characters, which is relatively short and consistent with a regulatory announcement. This fits the category of Regulatory Filings (RNS), as it is a regulatory announcement about auditor changes and not a full audit report or annual report.
2016-08-26 English
PRIMARY DOCUMENT
Director's Dealing
2016-08-09 English
PRIMARY DOCUMENT
Director's Dealing
2016-08-09 English
10-Q
Interim / Quarterly Report Q2 2016
2016-08-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.